<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> and <z:e sem="disease" ids="C0024790" disease_type="Disease or Syndrome" abbrv="PNH">paroxysmal nocturnal haemoglobinuria</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) are closely related disorders </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>, haematopoietic stem cells that harbour PIGA mutations give rise to blood elements that are unable to synthesize <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi> (GPI) anchors </plain></SENT>
<SENT sid="2" pm="."><plain>Because the GPI anchor is the receptor for the channel-forming protein aerolysin, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> cells do not bind the toxin and are unaffected by concentrations that lyse <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Exploiting these biological differences, we have developed two novel aerolysin-based assays to detect small populations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>CD59 populations as small as 0.004% of total red cells could be detected when cells were pretreated with aerolysin to enrich the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> population </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> patients displayed CD59-deficient erythrocytes, but no <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patient or control had detectable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> cells before or after enrichment in aerolysin </plain></SENT>
<SENT sid="6" pm="."><plain>Only one aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> patient had detectable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> red cells before exposure to aerolysin </plain></SENT>
<SENT sid="7" pm="."><plain>However, 14 (61%) had detectable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> cells after enrichment in aerolysin </plain></SENT>
<SENT sid="8" pm="."><plain>The inactive fluorescent proaerolysin variant (FLAER) that binds the GPI anchors of a number of proteins on <z:mpath ids='MPATH_458'>normal</z:mpath> cells was used to detect a global GPI anchor deficit on granulocytes </plain></SENT>
<SENT sid="9" pm="."><plain>Flow cytometry with FLAER showed that 12 out of 18 (67%) aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> patients had FLAER-negative granulocytes, but none of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients or <z:mpath ids='MPATH_458'>normal</z:mpath> control subjects had GPI anchor-deficient cells </plain></SENT>
<SENT sid="10" pm="."><plain>These studies demonstrate that aerolysin-based assays can reveal previously undetectable multilineage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> cells in patients with untreated aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, clonality appears to be an early feature of aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> </plain></SENT>
</text></document>